G. Kim

Empagliflozin as add‐on to metformin in people with Type 2 diabetes

U. Broedl, H. Woerle, H. Woerle, 2015, Diabetic medicine : a journal of the British Diabetic Association.

Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial

J. Rosenstock, U. Broedl, H. Woerle, 2015, Diabetes, obesity & metabolism.

Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with Type 2 Diabetes (T2DM): Pooled data from four pivotal phase III trials

U. Broedl, J. Gerich, H. Woerle, 2014 .

Empagliflozin (EMPA) increases genital infections but not Urinary Tract Infections (UTIs) in pooled data from four pivotal phase III trials

U. Broedl, J. Gerich, H. Woerle, 2014 .

Long‐term treatment with empagliflozin as add‐on to oral antidiabetes therapy in Japanese patients with type 2 diabetes mellitus

E. Araki, U. Broedl, H. Woerle, 2015, Diabetes, obesity & metabolism.

Cardiovascular safety of empagliflozin in patients with type 2 diabetes: a meta‐analysis of data from randomized placebo‐controlled trials

U. Broedl, H. Woerle, H. Woerle, 2016, Diabetes, obesity & metabolism.

Empagliflozin (EMPA) Compared with Glimepiride (GLIM) as Add-On to Metformin (MET) for 2 Years in Patients with Type 2 Diabetes (T2DM)

M. Ridderstråle, U. Broedl, H. Woerle, 2014 .

Empagliflozin as Add On to Basal Insulin for 78 Weeks Improves Glycemic Control with Weight Loss in Insulin-Treated Type 2 Diabetes (T2DM)

J. Rosenstock, U. Broedl, H. Woerle, 2013 .